{{Drugbox
| Watchedfields = changed
| verifiedrevid = 458958452
| IUPAC_name = 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-'''N'''-sulfamoylpropanimidamide
| image = Famotidine.svg
| width = 275
| image2 = Famotidine ball-and-stick model.png

<!--Clinical data-->
| pronounce = {{IPAc-en|f|ə|ˈ|m|ɒ|t|ɪ|d|iː|n}}
| tradename = Pepcid, others
| Drugs.com = {{drugs.com|monograph|famotidine}}
| MedlinePlus = a687011
| licence_US = Famotidine
| pregnancy_AU = B1
| pregnancy_US = B
| legal_AU = S3
| legal_AU_comment = /S4; pharmacist only
| legal_UK = GSL
| legal_US = OTC
| routes_of_administration = Oral ([[Tablet (pharmacy)|tablets]]), Intravenous

<!--Pharmacokinetic data-->
| bioavailability = 40–45% (oral)<ref name = DP />
| protein_bound = 15–20%<ref name = DP />
| metabolism = hepatic
| elimination_half-life = 2.5–3.5 hours<ref name = DP />
| excretion = Renal (25-30% unchanged [Oral])<ref name = DP>Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Oct 10]. Greenwood Village, CO: Thomsen Healthcare; 2013.</ref>

<!--Identifiers-->
| IUPHAR_ligand = 7074
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 76824-35-6
| ATC_prefix = A02
| ATC_suffix = BA03
| PubChem = 3325
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00927
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3208
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5QZO15J2Z8
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00318
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4975
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 902

<!--Chemical data-->
| C=8 | H=15 | N=7 | O=2 | S=3
| molecular_weight = 337.449 g/mol
| smiles = NS(=O)(=O)/N=C(\N)CCSCc1csc(n1)N=C(N)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XUFQPHANEAPEMJ-UHFFFAOYSA-N
}}

'''Famotidine''', sold under the trade name '''Pepcid''' among others, is a [[H2 antagonist|histamine H<sub>2</sub> receptor antagonist]] that inhibits [[gastric acid|stomach acid]] production. It is commonly used in the treatment of  [[peptic ulcer]] disease and [[gastroesophageal reflux]] disease.

Unlike [[cimetidine]], the first H<sub>2</sub> antagonist, famotidine has no effect on the [[cytochrome P450]] enzyme system, and does not appear to [[drug interaction|interact with other drugs]].<ref>{{cite journal | author = Humphries TJ, Merritt GJ | title = Review article: drug interactions with agents used to treat acid-related diseases | journal = Aliment. Pharmacol. Ther. |date=August 1999 | volume = 13 | issue = Suppl 3 | pages = 18–26  | pmid = 10491725 | doi = 10.1046/j.1365-2036.1999.00021.x | url = http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.1999.00021.x/pdf | format = pdf  }}</ref>

It was discovered in 1979.<ref>{{cite book|last1=Fischer|first1=Janos|title=Analogue-based Drug Discovery II|date=2010|publisher=John Wiley & Sons|page=4|isbn=978-3-527-63212-1|url=https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA4}}</ref>

== Medical uses ==
* Relief of [[heartburn]], acid indigestion, and sour stomach
* Treatment for [[gastric ulcers|gastric]] and [[duodenal ulcers]]
* Treatment for pathologic gastrointestinal hypersecretory conditions such as [[Zollinger–Ellison syndrome]] and [[Multiple endocrine neoplasia|multiple endocrine adenomas]]
* Treatment for [[gastroesophageal reflux disease]] (GERD)
* Treatment for [[esophagitis]]
* Part of a multidrug regimen for ''[[Helicobacter pylori]]'' eradication, although [[omeprazole]] may be somewhat more effective.<ref>{{cite journal|last1=Kanayama|first1=S|title=Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication |journal=Nihon rinsho. Japanese journal of clinical medicine |date=January 1999|volume=57|issue=1|pages=153–6|pmid=10036954}}</ref><ref>{{cite journal|last1=Soga|first1=T|last2=Matsuura|first2=M|last3=Kodama|first3=Y|last4=Fujita|first4=T|last5=Sekimoto|first5=I|last6=Nishimura|first6=K|last7=Yoshida|first7=S|last8=Kutsumi|first8=H|last9=Fujimoto|first9=S|title=Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?|journal=Journal of gastroenterology|date=August 1999|volume=34|issue=4|pages=435–40|pmid=10452673|doi=10.1007/s005350050292}}</ref><ref>{{cite journal|last1=Borody|first1=TJ|last2=Andrews|first2=P|last3=Fracchia|first3=G|last4=Brandl|first4=S|last5=Shortis|first5=NP|last6=Bae|first6=H|title=Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.|journal=Gut|date=October 1995|volume=37|issue=4|pages=477–81|pmid=7489931|doi=10.1136/gut.37.4.477|pmc=1382896}}</ref><ref>{{cite journal|last1=Hu|first1=FL|last2=Jia|first2=JC|last3=Li|first3=YL|last4=Yang|first4=GB|title=Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.|journal=The Journal of international medical research|date=2003|volume=31|issue=6|pages=469–74|pmid=14708410|doi=10.1177/147323000303100601}}</ref><ref>{{cite journal|last1=Kirika|first1=NV|last2=Bodrug|first2=NI|last3=Butorov|first3=IV|last4=Butorov|first4=SI|title=[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].|journal=Terapevticheskii arkhiv|date=2004|volume=76|issue=2|pages=18–22|pmid=15106408}}</ref><ref>{{cite journal|last1=Fujiwara|first1=Y|last2=Higuchi|first2=K|last3=Nebiki|first3=H|last4=Chono|first4=S|last5=Uno|first5=H|last6=Kitada|first6=K|last7=Satoh|first7=H|last8=Nakagawa|first8=K|last9=Kobayashi|first9=K|last10=Tominaga|first10=K|last11=Watanabe|first11=T|last12=Oshitani|first12=N|last13=Arakawa|first13=T|title=Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.|journal=Alimentary pharmacology & therapeutics|date=June 2005|volume=21 Suppl 2|pages=10–8|pmid=15943841|doi=10.1111/j.1365-2036.2005.02468.x}}</ref>
* Prevention of [[Nonsteroidal anti-inflammatory drug|NSAID]]-induced peptic ulcers.<ref>{{cite journal|last1=La Corte|first1=R|last2=Caselli|first2=M|last3=Castellino|first3=G|last4=Bajocchi|first4=G|last5=Trotta|first5=F|title=Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.|journal=Drug safety|date=June 1999|volume=20|issue=6|pages=527–43|pmid=10392669|doi=10.2165/00002018-199920060-00006}}</ref><ref>{{cite journal|last1=Laine|first1=L|last2=Kivitz|first2=AJ|last3=Bello|first3=AE|last4=Grahn|first4=AY|last5=Schiff|first5=MH|last6=Taha|first6=AS|title=Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.|journal=The American journal of gastroenterology|date=March 2012|volume=107|issue=3|pages=379–86|doi=10.1038/ajg.2011.443|pmid=22186979|pmc=3321505}}</ref>
* Given to surgery patients before operations to reduce the risk of [[Aspiration pneumonia|aspiration pneumonitis]].<ref>{{cite journal|last1=Escolano|first1=F|last2=Castaño|first2=J|last3=López|first3=R|last4=Bisbe|first4=E|last5=Alcón|first5=A|title=Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery.|journal=British journal of anaesthesia|date=October 1992|volume=69|issue=4|pages=404–6|pmid=1419452|doi=10.1093/bja/69.4.404}}</ref><ref>{{cite journal|last1=Vila|first1=P|last2=Vallès|first2=J|last3=Canet|first3=J|last4=Melero|first4=A|last5=Vidal|first5=F|title=Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine.|journal=Anaesthesia|date=November 1991|volume=46|issue=11|pages=967–9|pmid=1750602|doi=10.1111/j.1365-2044.1991.tb09860.x}}</ref><ref>{{cite journal|last1=Jahr|first1=JS|last2=Burckart|first2=G|last3=Smith|first3=SS|last4=Shapiro|first4=J|last5=Cook|first5=DR|title=Effects of famotidine on gastric pH and residual volume in pediatric surgery.|journal=Acta anaesthesiologica Scandinavica|date=July 1991|volume=35|issue=5|pages=457–60|pmid=1887750|doi=10.1111/j.1399-6576.1991.tb03328.x}}</ref>

Famotidine is also given to dogs and cats with acid reflux.<ref>{{cite web|url=http://www.petmd.com/pet-medication/famotidine|title=Famotidine|publisher=}}</ref> Famotidine has been used in combination with an [[H1 antagonist|H<sub>1</sub> antagonist]] to treat and prevent [[Urticaria#Histamine antagonists|urticaria]] caused by an acute allergic reaction.<ref>{{cite web | url = http://www.bestbets.org/bets/bet.php?id=353 | title = Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions | author = Fogg TB, Semple D | date = 29 November 2007 | work = BestBets | publisher = [[Manchester Royal Infirmary]] | location = Manchester, England | accessdate = 26 April 2011 }}</ref>

=== Preparations ===
Certain preparations of famotidine are available [[Over-the-counter drug|over the counter]] (OTC) in various countries. In the United States and Canada, 10&nbsp;mg and 20&nbsp;mg tablets, sometimes in combination with an [[antacid]],<ref>[[Pepcid Complete]]</ref><ref>{{cite web|url=http://www.nlm.nih.gov/medlineplus/druginfo/meds/a687011.html|title=Famotidine|publisher=}}</ref> are available OTC. Larger doses still require a medical prescription.

Formulations of famotidine in combination with [[ibuprofen]] were marketed by [[Horizon Pharma]] under the trade name Duexis.<ref>Drugs.com {{Drugs.com|parent|duexis}}</ref>

== Side effects ==
Side effects associated with famotidine use include [[headache]], [[dizziness]], and [[constipation]] or [[diarrhea]].<ref>{{cite web | url = http://www.rxlist.com/cgi/generic/famot_ad.htm | title = Pepcid Side Effects & Drug Interactions | year = 2008 | accessdate=31 July 2008 | publisher = RxList.com }}</ref>

== History ==
Famotidine was developed by [[Yamanouchi Pharmaceutical]] Co.<ref>{{US patent reference |number=4283408 |issue-date=11 August 1981 |inventor=Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda | title = Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them }}</ref> It was licensed in the mid-1980s by [[Merck & Co.]]<ref>{{cite web|url=http://mediwire.skyscape.com/main/Default.aspx?P=Content&ArticleID=23882 |title=Sankyo Pharma |publisher=Skyscape Mediwire |year=2002 |accessdate=31 October 2009 |deadurl=yes |archiveurl=https://web.archive.org/web/20090223125527/http://mediwire.skyscape.com/main/Default.aspx?P=Content&ArticleID=23882 |archivedate=23 February 2009 }}</ref> and is marketed by a joint venture between Merck and Johnson & Johnson. The [[imidazole]] ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be nine times more potent than [[ranitidine]], and thirty-two times more potent than [[cimetidine]].<ref>{{cite journal|last1=Howard|first1=JM|last2=Chremos|first2=AN|last3=Collen|first3=MJ|last4=McArthur|first4=KE|last5=Cherner|first5=JA|last6=Maton|first6=PN|last7=Ciarleglio|first7=CA|last8=Cornelius|first8=MJ|last9=Gardner|first9=JD|last10=Jensen|first10=RT|title=Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.|journal=Gastroenterology|date=April 1985|volume=88|issue=4|pages=1026–33|pmid=2857672}}</ref>

It was first marketed in 1981. Pepcid RPD [[orally disintegrating tablet]]s were released in 1999. Generic preparations became available in 2001, e.g. Fluxid ([[Schwarz Pharma|Schwarz]]) or Quamatel ([[Gedeon Richter Ltd.]]).

In the United States and Canada, a product called [[Pepcid Complete]], which combines famotidine with an [[antacid]] in a chewable tablet to quickly relieve the symptoms of excess stomach acid, is available. In the UK, this product was known as Pepcidtwo prior to its discontinuation in April 2015.<ref>{{cite web|url=http://www.medicines.org.uk/emc/medicine/20012|title=PepcidTwo Chewable Tablet|accessdate=7 June 2015}}</ref>

Famotidine suffers from poor [[bioavailability]] (50%), as it is poorly soluble in the low pH of the stomach. When used in combination with antacids, it promotes local delivery of these drugs to the receptor of the parietal cell wall. Therefore, researchers are developing innovative formulations of tablets, such as gastroretentive drug delivery systems. Such tablets are retained in the stomach for a longer period of time, thereby improving the bioavailability of drugs. Local delivery also increases bioavailability at the stomach wall receptor site and increases the efficacy of drugs to reduce acid secretion.<ref>{{cite web |url =http://www.farmavita.net/content/view/1012/84/ |title = Formulation and Evaluation of Gastroretentive Floating Tablets of Famotidine |year = 2008 |accessdate=31 January 2009 |publisher = Farmavita.Net}}</ref>

== Research ==
Famotidine has been investigated as an adjunct in treatment-resistant [[schizophrenia]]. In one trial, it caused a 10% reduction in schizophrenic symptom severity in treatment-resistant patients.<ref>{{cite journal|last=Meskanen|first=K|author2=Ekelund, H |author3=Laitinen, J |author4=Neuvonen, PJ |author5=Haukka, J |author6=Panula, P |author7= Ekelund, J |title=A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.|journal=Journal of Clinical Psychopharmacology|date=August 2013|volume=33|issue=4|pages=472–478|doi=10.1097/JCP.0b013e3182970490|pmid=23764683}}</ref>

== See also ==
* [[Ranitidine]], another popular H<sub>2</sub> receptor antagonist
* [[Nizatidine]]

== References ==
{{Reflist}}
{{-}}

{{Histaminergics}}
{{Drugs for peptic ulcer and GORD}}

[[Category:Amidines]]
[[Category:Guanidines]]
[[Category:H2 receptor antagonists]]
[[Category:Sulfonamides]]
[[Category:Thiazoles]]
[[Category:Thioethers]]